Long-term effects of breast cancer treatment on heart function
Breast Cancer Long-term Outcomes on Cardiac Functioning: a Longitudinal Study
University Medical Center Groningen · NCT05851053
This study looks at how breast cancer treatments affect heart health in women who survived breast cancer to see if any heart problems they had in the past might get worse over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 455 (estimated) |
| Sex | Female |
| Sponsor | University Medical Center Groningen (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Groningen) |
| Trial ID | NCT05851053 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the long-term cardiac outcomes in female breast cancer survivors who received chemotherapy and/or radiotherapy. It will include participants from a previous study who were diagnosed with stage I-III breast cancer at least five years ago. The study will utilize echocardiography to assess cardiac function and determine if mild cardiac dysfunction observed in previous research predicts further deterioration. The findings could help clarify the risks associated with breast cancer treatments and inform clinical guidelines.
Who should consider this trial
Good fit: Ideal candidates are females diagnosed with stage I-III breast cancer at least five years ago who have undergone chemotherapy and/or radiotherapy.
Not a fit: Patients with metastatic breast cancer at diagnosis or those who received treatment after the age of 80 may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and management of cardiac health in breast cancer survivors.
How similar studies have performed: Previous studies have indicated a risk of cardiac dysfunction in breast cancer survivors, suggesting this approach is based on established findings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who previously took part in de BLOC-I study will be included. These criteria were: * females diagnosed with stage I-III BC at least five years ago or local or locoregional recurrence of BC at least five years ago * treatment with chemotherapy and/or radiotherapy. Exclusion Criteria: * Patients unfit to travel to the hospital due to severe mental or physical illness, based on assessment by their GP. Exclusion criteria for the BC survivors in the BLOC-I study were: * metastatic disease at the time of BC diagnosis; * BC treatment after 80 years of age; * history of treatment for other types of cancer.
Where this trial is running
Groningen
- University Medical Center Groningen — Groningen, Netherlands (RECRUITING)
Study contacts
- Study coordinator: Daan Brandenbarg, PhD
- Email: d.brandenbarg@umcg.nl
- Phone: 0031628475305
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Neoplasm, Breast, Heart Failure, Cardiotoxicity, Ventricular Dysfunction, Breast cancer, Heart failure